Literature DB >> 32439433

Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype.

Nontaya Nakkam1, Andrew Gibson2, Effie Mouhtouris3, Katherine C Konvinse4, Natasha E Holmes3, Kyra Y Chua3, Pooja Deshpande5, Danmeng Li6, David A Ostrov6, Jason Trubiano7, Elizabeth J Phillips8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32439433      PMCID： PMC7674263          DOI： 10.1016/j.jaci.2020.04.056

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

Review 2.  Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.

Authors:  Linda J Zhu; Anne Y Liu; Priscilla H Wong; Anna Chen Arroyo
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-29       Impact factor: 10.817

3.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 4.  Role of pharmacogenomics in T-cell hypersensitivity drug reactions.

Authors:  Rebecca J Hertzman; Pooja Deshpande; Andrew Gibson; Elizabeth J Phillips
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-08-01

Review 5.  Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.

Authors:  Yueran Li; Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Andrew Gibson; Elizabeth J Phillips
Journal:  Front Genet       Date:  2021-04-16       Impact factor: 4.599

Review 6.  Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.

Authors:  Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips
Journal:  Clin Pharmacol Ther       Date:  2021-07-17       Impact factor: 6.875

7.  Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication.

Authors:  Funmilola Josephine Haukamp; Eline Gall; Gia-Gia Toni Hò; Wiebke Hiemisch; Florian Stieglitz; Joachim Kuhn; Rainer Blasczyk; Andreas Pich; Christina Bade-Döding
Journal:  J Pers Med       Date:  2022-01-04

8.  Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects.

Authors:  Eline Gall; Florian Stieglitz; Andreas Pich; Georg Martin Norbert Behrens; Joachim Kuhn; Rainer Blasczyk; Funmilola Josephine Haukamp; Christina Bade-Döding
Journal:  Biomedicines       Date:  2022-03-17

9.  Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01.

Authors:  Joshua Gardner; Monday Ogese; Catherine J Betts; Munir Pirmohamed; Dean J Naisbitt
Journal:  Chem Res Toxicol       Date:  2022-02-02       Impact factor: 3.739
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.